Buscar
Liquidia Corp
LQDAAñadir a la lista de seguimiento
56.930USD
-2.370-4.00%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
5.06BCap. mercado
227.51P/E TTM
Más Datos de Liquidia Corp Compañía
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Información de Liquidia Corp
Símbolo de cotizaciónLQDA
Nombre de la empresaLiquidia Corp
Fecha de salida a bolsaJul 26, 2018
Director ejecutivoJeffs (Roger A)
Número de empleados157
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 26
Dirección419 Davis Drive
CiudadMORRISVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27560
Teléfono19193284400
Sitio Webhttps://www.liquidia.com/
Símbolo de cotizaciónLQDA
Fecha de salida a bolsaJul 26, 2018
Director ejecutivoJeffs (Roger A)
Ejecutivos de Liquidia Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.18M
-2.25%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
453.86K
+11.11%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
181.65K
+1.24%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
130.44K
-10.97%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
66.29K
-167.81%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
52.36K
+3.75%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
51.06K
-227.72%
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
20.36K
+9.64%
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
15.36K
+12.78%
Dr. Stephen M. Bloch
Dr. Stephen M. Bloch
Independent Chairman of the board
Independent Chairman of the board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.18M
-2.25%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
453.86K
+11.11%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
181.65K
+1.24%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
130.44K
-10.97%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
66.29K
-167.81%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
52.36K
+3.75%
Desglose de ingresos
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
14.00M
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 14 de may
Actualizado: jue., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Farallon Capital Management, L.L.C.
9.73%
Caligan Partners, LP
9.13%
Manning (Paul B.)
6.18%
BlackRock Institutional Trust Company, N.A.
5.33%
Vanguard Capital Management, LLC
3.29%
Otro
66.34%
Accionistas
Accionistas
Proporción
Farallon Capital Management, L.L.C.
9.73%
Caligan Partners, LP
9.13%
Manning (Paul B.)
6.18%
BlackRock Institutional Trust Company, N.A.
5.33%
Vanguard Capital Management, LLC
3.29%
Otro
66.34%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
32.61%
Investment Advisor
20.58%
Investment Advisor/Hedge Fund
10.64%
Individual Investor
10.32%
Research Firm
3.41%
Corporation
2.58%
Family Office
2.01%
Private Equity
0.79%
Bank and Trust
0.48%
Otro
16.59%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
439
65.17M
73.52%
-6.80M
2025Q4
388
63.95M
73.51%
-2.03M
2025Q3
358
61.00M
70.12%
+1.28M
2025Q2
350
67.92M
79.46%
-5.32M
2025Q1
356
67.75M
79.47%
-4.91M
2024Q4
344
63.62M
75.17%
-10.09M
2024Q3
335
73.31M
89.39%
+16.42M
2024Q2
318
66.67M
87.88%
+4.98M
2024Q1
302
59.34M
79.61%
+7.64M
2023Q4
256
48.15M
70.41%
+4.56M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Farallon Capital Management, L.L.C.
8.66M
9.82%
+90.40K
+1.06%
Dec 31, 2025
Caligan Partners, LP
8.12M
9.21%
--
--
Dec 31, 2025
Manning (Paul B.)
6.22M
7.06%
+55.12K
+0.89%
Feb 11, 2026
BlackRock Institutional Trust Company, N.A.
4.74M
5.38%
+169.34K
+3.71%
Dec 31, 2025
Findell Capital Management LLC
2.85M
3.24%
+21.45K
+0.76%
Dec 31, 2025
Opaleye Management Inc.
2.44M
2.76%
-180.00K
-6.88%
Dec 31, 2025
Jeffs (Roger A)
2.23M
2.53%
+119.90K
+5.68%
Jan 16, 2026
Legend Aggregator LP
1.86M
2.11%
-5.32M
-74.10%
Dec 31, 2024
State Street Investment Management (US)
1.81M
2.05%
-105.00K
-5.49%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.68%
State Street SPDR S&P Pharmaceuticals ETF
2.33%
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
1.07%
First Trust Small Cap Growth AlphaDEX Fund
0.83%
iShares U.S. Pharmaceuticals ETF
0.61%
Federated Hermes MDT Small Cap Core ETF
0.41%
First Trust Small Cap Core Alphadex Fund
0.34%
iShares Micro-Cap ETF
0.3%
State Street SPDR S&P Kensho New Econ Comp ETF
0.27%
Ver más
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción2.68%
State Street SPDR S&P Pharmaceuticals ETF
Proporción2.33%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción1.07%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.83%
iShares U.S. Pharmaceuticals ETF
Proporción0.61%
Federated Hermes MDT Small Cap Core ETF
Proporción0.41%
First Trust Small Cap Core Alphadex Fund
Proporción0.34%
iShares Micro-Cap ETF
Proporción0.3%
State Street SPDR S&P Kensho New Econ Comp ETF
Proporción0.27%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
